- Home
- ANAB vs GES Comparison
ANAB vs GES Comparison
Compare ANAB & GES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- GES
- Stock Information
- Founded
- ANAB 2005
- GES 1981
- Country
- ANAB United States
- GES Switzerland
- Employees
- ANAB N/A
- GES N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- GES Apparel
- Sector
- ANAB Health Care
- GES Consumer Discretionary
- Exchange
- ANAB Nasdaq
- GES Nasdaq
- Market Cap
- ANAB 1.0B
- GES 872.4M
- IPO Year
- ANAB 2017
- GES 1996
- Fundamental
- Price
- ANAB $38.47
- GES $16.95
- Analyst Decision
- ANAB Buy
- GES Buy
- Analyst Count
- ANAB 12
- GES 5
- Target Price
- ANAB $63.30
- GES $19.25
- AVG Volume (30 Days)
- ANAB 364.4K
- GES 597.7K
- Earning Date
- ANAB 11-04-2025
- GES 11-25-2025
- Dividend Yield
- ANAB N/A
- GES 5.31%
- EPS Growth
- ANAB N/A
- GES N/A
- EPS
- ANAB N/A
- GES 0.35
- Revenue
- ANAB $169,467,000.00
- GES $3,091,508,000.00
- Revenue This Year
- ANAB $37.52
- GES $7.97
- Revenue Next Year
- ANAB N/A
- GES $3.46
- P/E Ratio
- ANAB N/A
- GES $48.87
- Revenue Growth
- ANAB 196.42
- GES 7.84
- 52 Week Low
- ANAB $12.21
- GES $8.48
- 52 Week High
- ANAB $40.96
- GES $18.07
- Technical
- Relative Strength Index (RSI)
- ANAB 72.78
- GES 61.57
- Support Level
- ANAB $34.22
- GES $16.87
- Resistance Level
- ANAB $37.08
- GES $17.02
- Average True Range (ATR)
- ANAB 2.03
- GES 0.07
- MACD
- ANAB -0.18
- GES -0.03
- Stochastic Oscillator
- ANAB 68.07
- GES 61.22
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About GES Guess? Inc.
Guess? Inc designs, markets distributes, and licenses contemporary apparel and accessories that reflect European fashion sensibilities and American Lifestyle under brands including Guess, Marciano, and G by Guess. The company has five reportable segments: Americas Retail, Americas Wholesale, Europe, Asia, and licensing. Geographically, the company derives maximum revenue from the United States.